New genetic mutations found for non-Hodgkin lymphoma
Scientists at the BC Cancer Agency in British Columbia, Canada and their U.S. collaborators have identified a number of new genetic mutations involved in non-Hodgkin lymphoma, or NHL.
View ArticleResearchers’ blood cancer breakthrough
Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can...
View ArticleTriple therapy regime puts patients with leukemic form of cutaneous lymphoma...
A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson...
View ArticleMore intensive chemotherapy dramatically improves recurrence, survival in...
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain...
View ArticleAutologous stem cell transplantation does not improve os in patients with...
High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with...
View ArticleRadiation ups event-free, not overall survival in ped Hodgkin's
(HealthDay) -- For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy (IFRT) improves event-free survival (EFS), but has no...
View ArticleNew therapy on the horizon for ALK+ non-small cell lung cancer
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who...
View ArticleMutations in JAK3 gene identified in subtype of lymphoma provide potential...
A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study...
View ArticleProgress in quest to reduce use of radiation in treatment of pediatric...
A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at...
View ArticleNew drug dramatically improves survival in Hodgkin lymphoma patients
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
View ArticleB cell survival holds key to chronic graft vs. host disease
Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and...
View ArticleMutation ID'd in Waldenstrom's macroglobulinemia
(HealthDay)—MYD88 L265P is a common, recurring mutation in patients with Waldenström's macroglobulinemia, according to a study published in the Aug. 30 issue of the New England Journal of Medicine.
View ArticleMelanoma up to 2.5 times likelier to strike transplant, lymphoma patients
Melanoma is on the rise nationally, and transplant recipients and lymphoma patients are far likelier than the average person to get that form of skin cancer and to die from it, a Mayo Clinic review has...
View ArticleWomen respond better to the treatment of lymph gland cancer with antibodies...
(Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre,...
View ArticleScientists harness immune system to prevent lymphoma relapse
UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results.
View ArticleTriptorelin doesn't avert early ovarian failure in lymphoma
(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian...
View ArticleGenome sequencing of Burkitt Lymphoma reveals unique mutation
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been...
View ArticleNovel drug therapy targets aggressive form of non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called...
View ArticleEpigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics...
View ArticleCured of cancer but in poor health
The majority of people afflicted with cancer now recover with treatment. Many of these, however, subsequently experience new health problems due to the cancer and/or the treatment. Norwegian...
View Article
More Pages to Explore .....